Quantcast
Last updated on April 24, 2014 at 17:35 EDT

Product Differentiation to Boost European Human Growth Hormones Market, Says Frost & Sullivan

March 6, 2013

Strategic collaborations with drug delivery companies will help in the development of innovative offerings

LONDON, March 6, 2013 /PRNewswire/ — The stable growth of the European human growth hormone (hGH) market is attributed primarily to a decrease in the prices and an increase in the overall volumes of hGH drugs used.

No new indications for hGH therapy are likely to be approved by the European Medicines Agency (EMEA) over the next 3 to 5 years. This, paralleled by a stable patient population, has resulted in a saturated market that does not provide attractive opportunities for new entrants. Nevertheless, product differentiation based on innovative technologies will enable existing market participants to expand their share in this highly concentrated market.

New analysis from Frost & Sullivan (http://www.lifesciences.frost.com), European Human Growth Hormones Market, finds that the market earned $0.99 billion in 2012 and estimates this to reach $1.22 billion in 2019. The research covers adult and paediatric segments.

“Product differentiation in the hGH market is aimed at 3 different levels; namely, drug delivery mechanisms, long-acting preparations and improved formulations, and combination therapy,” notes Frost & Sullivan Senior Research Analyst Aiswariya Chidambaram. “Companies have increasingly started to focus on developing non-invasive delivery methods to improve patient compliance and reduce treatment withdrawal rates.”

Such efforts are set to address the issue of reduced therapeutic efficacy due to poor patient compliance. With more than 80% of the target population for hGH being children below the age of 15 years, taking hGH injections on a daily basis is a major challenge. This has led to poor adherence and higher withdrawal rates from existing therapeutic regimes.

Entering into strategic collaborations with drug delivery companies could pave the way for product differentiation, while enabling market participants to gain a competitive advantage.

“Fostering strategic alliances with technology providers and drug delivery companies will help hGH manufacturers to develop other potential modes of drug delivery such as oral and pulmonary,” concludes Chidambaram. “Such non-invasive drug delivery methods are likely to motivate improved patient compliance and treatment success rates.”

If you are interested in more information on this research, please send an email to Anna Zanchi, Corporate Communications, at anna.zanchi@frost.com

European Human Growth Hormones Market is part of the Life Sciences Growth Partnership Service programme. Frost & Sullivan’s related research services include: European Biosimilars Market, European Vaccines Market, and European Pharmaceutical and Biotech Contract Manufacturing Market. All research included in subscriptions provide detailed market opportunities and industry trends that have been evaluated following extensive interviews with market participants.

About Frost & Sullivan
Frost & Sullivan, the Growth Partnership Company, works in collaboration with clients to leverage visionary innovation that addresses the global challenges and related growth opportunities that will make or break today’s market participants.

Our “Growth Partnership” supports clients by addressing these opportunities and incorporating two key elements driving visionary innovation: The Integrated Value Proposition and The Partnership Infrastructure.

  • The Integrated Value Proposition provides support to our clients throughout all phases of their journey to visionary innovation including: research, analysis, strategy, vision, innovation and implementation.
  • The Partnership Infrastructure is entirely unique as it constructs the foundation upon which visionary innovation becomes possible. This includes our 360 degree research, comprehensive industry coverage, career best practices as well as our global footprint of more than 40 offices.

For more than 50 years, we have been developing growth strategies for the global 1000, emerging businesses, the public sector and the investment community. Is your organisation prepared for the next profound wave of industry convergence, disruptive technologies, increasing competitive intensity, Mega Trends, breakthrough best practices, changing customer dynamics and emerging economies?

Contact Us: Start the discussion
Join Us: Join our community
Subscribe: Newsletter on “the next big thing”
Register: Gain access to visionary innovation

Contact
Anna Zanchi
Corporate Communications – Europe
P: +39.02.4851 6133
E: anna.zanchi@frost.com
http://www.frost.com

SOURCE Frost & Sullivan


Source: PR Newswire